Dr. Reddy's Laboratories Limited (RDY)
USD 14.55
(0.48%)
USD 14.55
(0.48%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 5.99 Billion INR | 0.0% |
| 2023 | 1.27 Billion INR | -77.76% |
| 2022 | 5.74 Billion INR | -8.78% |
| 2021 | 6.29 Billion INR | 383.05% |
| 2020 | 1.3 Billion INR | -94.07% |
| 2019 | 22 Billion INR | -12.31% |
| 2018 | 25.08 Billion INR | 360.43% |
| 2017 | 5.44 Billion INR | -49.0% |
| 2016 | 10.68 Billion INR | -25.32% |
| 2015 | 14.3 Billion INR | -31.02% |
| 2014 | 20.74 Billion INR | -83.57% |
| 2013 | 126.24 Billion INR | 672.86% |
| 2012 | 16.33 Billion INR | 207.28% |
| 2011 | 5.31 Billion INR | -1.28% |
| 2010 | 5.38 Billion INR | -46.85% |
| 2009 | 10.13 Billion INR | -21.24% |
| 2008 | 12.86 Billion INR | -28.19% |
| 2007 | 17.91 Billion INR | -14.66% |
| 2006 | 20.99 Billion INR | 83354.69% |
| 2005 | 25.15 Million INR | -19.25% |
| 2004 | 31.14 Million INR | -23.66% |
| 2003 | 40.8 Million INR | -13.13% |
| 2002 | 46.97 Million INR | -95.3% |
| 2001 | 999.73 Million INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 4.93 Billion INR | 0.0% |
| 2024 Q3 | 6.15 Billion INR | 0.0% |
| 2024 FY | 5.99 Billion INR | 368.7% |
| 2024 Q4 | 5.99 Billion INR | 0.0% |
| 2024 Q2 | 6.04 Billion INR | 0.0% |
| 2023 Q3 | 1.45 Billion INR | -18.83% |
| 2023 Q1 | 1.9 Billion INR | -66.88% |
| 2023 FY | 1.27 Billion INR | -77.76% |
| 2023 Q4 | 1.27 Billion INR | -12.29% |
| 2023 Q2 | 1.79 Billion INR | -5.68% |
| 2022 Q1 | 6.16 Billion INR | -2.11% |
| 2022 FY | 5.74 Billion INR | -8.78% |
| 2022 Q2 | 5.97 Billion INR | -3.07% |
| 2022 Q4 | 5.74 Billion INR | -4.76% |
| 2022 Q3 | 6.03 Billion INR | 0.94% |
| 2021 Q2 | 6.66 Billion INR | -1.89% |
| 2021 FY | 6.29 Billion INR | 383.05% |
| 2021 Q1 | 6.78 Billion INR | 420.63% |
| 2021 Q4 | 6.29 Billion INR | -3.21% |
| 2021 Q3 | 6.5 Billion INR | -2.3% |
| 2020 Q1 | 16.65 Billion INR | -24.29% |
| 2020 FY | 1.3 Billion INR | -94.07% |
| 2020 Q4 | 1.3 Billion INR | 4.65% |
| 2020 Q3 | 1.24 Billion INR | -91.85% |
| 2020 Q2 | 15.28 Billion INR | -8.24% |
| 2019 Q3 | 24.7 Billion INR | -10.5% |
| 2019 FY | 22 Billion INR | -12.31% |
| 2019 Q1 | 26.09 Billion INR | 4.02% |
| 2019 Q2 | 27.59 Billion INR | 5.75% |
| 2019 Q4 | 22 Billion INR | -10.93% |
| 2018 Q3 | 24.46 Billion INR | -1.97% |
| 2018 FY | 25.08 Billion INR | 360.43% |
| 2018 Q1 | 24.56 Billion INR | 350.72% |
| 2018 Q2 | 24.95 Billion INR | 1.6% |
| 2018 Q4 | 25.08 Billion INR | 2.57% |
| 2017 FY | 5.44 Billion INR | -49.0% |
| 2017 Q4 | 5.44 Billion INR | -4.69% |
| 2017 Q3 | 5.71 Billion INR | -46.45% |
| 2017 Q2 | 10.67 Billion INR | -1.57% |
| 2017 Q1 | 10.84 Billion INR | 1.52% |
| 2016 Q4 | 10.68 Billion INR | -0.07% |
| 2016 FY | 10.68 Billion INR | -25.32% |
| 2016 Q2 | 10.63 Billion INR | -12.01% |
| 2016 Q3 | 10.69 Billion INR | 0.56% |
| 2016 Q1 | 12.08 Billion INR | -15.54% |
| 2015 Q3 | 16.43 Billion INR | -8.13% |
| 2015 Q2 | 17.88 Billion INR | -6.86% |
| 2015 Q4 | 14.3 Billion INR | -12.93% |
| 2015 Q1 | 19.2 Billion INR | -7.41% |
| 2015 FY | 14.3 Billion INR | -31.02% |
| 2014 FY | 20.74 Billion INR | -83.57% |
| 2014 Q1 | 13.84 Billion INR | -89.03% |
| 2014 Q2 | 25.09 Billion INR | 81.28% |
| 2014 Q3 | 22.99 Billion INR | -8.36% |
| 2014 Q4 | 20.74 Billion INR | -9.81% |
| 2013 Q2 | 16.82 Billion INR | -3.3% |
| 2013 FY | 126.24 Billion INR | 672.86% |
| 2013 Q4 | 126.24 Billion INR | 628.78% |
| 2013 Q3 | 17.32 Billion INR | 2.97% |
| 2013 Q1 | 17.39 Billion INR | 6.51% |
| 2012 Q3 | 16.81 Billion INR | 217.55% |
| 2012 Q1 | 5.28 Billion INR | -0.56% |
| 2012 FY | 16.33 Billion INR | 207.28% |
| 2012 Q4 | 16.33 Billion INR | -2.83% |
| 2012 Q2 | 5.29 Billion INR | 0.15% |
| 2011 Q2 | 2.37 Billion INR | -43.87% |
| 2011 FY | 5.31 Billion INR | -1.28% |
| 2011 Q1 | 4.22 Billion INR | -21.52% |
| 2011 Q4 | 5.31 Billion INR | 2181.55% |
| 2011 Q3 | 233 Million INR | -90.18% |
| 2010 Q4 | 5.38 Billion INR | -22.75% |
| 2010 Q1 | 16.1 Billion INR | 58.98% |
| 2010 Q2 | 8.34 Billion INR | -48.18% |
| 2010 Q3 | 6.97 Billion INR | -16.48% |
| 2010 FY | 5.38 Billion INR | -46.85% |
| 2009 Q1 | 12.83 Billion INR | -0.23% |
| 2009 Q2 | 11.96 Billion INR | -6.74% |
| 2009 FY | 10.13 Billion INR | -21.24% |
| 2009 Q4 | 10.13 Billion INR | -9.83% |
| 2009 Q3 | 11.23 Billion INR | -6.11% |
| 2008 Q3 | 12.18 Billion INR | -0.8% |
| 2008 Q2 | 12.28 Billion INR | -0.92% |
| 2008 Q1 | 12.4 Billion INR | -30.78% |
| 2008 FY | 12.86 Billion INR | -28.19% |
| 2008 Q4 | 12.86 Billion INR | 5.55% |
| 2007 Q2 | 20.53 Billion INR | -5.63% |
| 2007 Q3 | 15.36 Billion INR | -25.16% |
| 2007 Q4 | 17.91 Billion INR | 16.55% |
| 2007 FY | 17.91 Billion INR | -14.66% |
| 2007 Q1 | 21.76 Billion INR | 3.67% |
| 2006 Q1 | 23.65 Million INR | -5.97% |
| 2006 Q3 | 20.71 Million INR | -6.69% |
| 2006 Q2 | 22.19 Million INR | -6.15% |
| 2006 Q4 | 20.99 Billion INR | 101246.54% |
| 2006 FY | 20.99 Billion INR | 83354.69% |
| 2005 Q1 | 29.56 Million INR | -5.09% |
| 2005 FY | 25.15 Million INR | -19.25% |
| 2005 Q2 | 28.11 Million INR | -4.88% |
| 2005 Q3 | 24.52 Million INR | -12.79% |
| 2005 Q4 | 25.15 Million INR | 2.57% |
| 2004 Q3 | 31.32 Million INR | -4.67% |
| 2004 Q4 | 31.14 Million INR | -0.56% |
| 2004 Q2 | 32.86 Million INR | -4.53% |
| 2004 FY | 31.14 Million INR | -23.66% |
| 2004 Q1 | 34.41 Million INR | -15.65% |
| 2003 FY | 40.8 Million INR | -13.13% |
| 2003 Q2 | 183.91 Million INR | 5.86% |
| 2003 Q1 | 173.72 Million INR | 269.85% |
| 2003 Q4 | 40.8 Million INR | -77.88% |
| 2003 Q3 | 184.5 Million INR | 0.32% |
| 2002 Q1 | 45.57 Million INR | 0.0% |
| 2002 FY | 46.97 Million INR | -95.3% |
| 2002 Q2 | 45.72 Million INR | 0.34% |
| 2002 Q3 | 45.2 Million INR | -1.14% |
| 2002 Q4 | 46.97 Million INR | 3.91% |
| 2001 FY | 999.73 Million INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 2.52 Billion USD | -137.425% |
| Bausch Health Companies Inc. | 21.93 Billion USD | 72.696% |
| Catalent, Inc. | 4.54 Billion USD | -31.793% |
| Emergent BioSolutions Inc. | 446.5 Million USD | -1241.545% |
| Elanco Animal Health Incorporated | 5.73 Billion USD | -4.428% |
| Perrigo Company plc | 3.63 Billion USD | -64.887% |
| Teva Pharmaceutical Industries Limited | 18.48 Billion USD | 67.588% |
| Zoetis Inc. | 6.56 Billion USD | 8.745% |